Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC)
Publication
, Journal Article
Armstrong, AJ; George, DJ; Halabi, S
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2010
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15
Publisher
AMER SOC CLINICAL ONCOLOGY
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., George, D. J., & Halabi, S. (2010). Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY, 28(15).
Armstrong, A. J., D. J. George, and S. Halabi. “Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC).” JOURNAL OF CLINICAL ONCOLOGY 28, no. 15 (May 20, 2010).
Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY. 2010 May 20;28(15).
Armstrong, A. J., et al. “Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 15, AMER SOC CLINICAL ONCOLOGY, May 2010.
Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTor inhibition in patients with metastatic renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2010 May 20;28(15).
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2010
Volume
28
Issue
15
Publisher
AMER SOC CLINICAL ONCOLOGY
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences